Follow
Ciara Metcalfe
Ciara Metcalfe
Scientist, Translational Oncology, Genentech
Verified email at gene.com
Title
Cited by
Cited by
Year
Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration
C Metcalfe, NM Kljavin, R Ybarra, FJ de Sauvage
Cell stem cell 14 (2), 149-159, 2014
5312014
Dynamic recruitment of axin by Dishevelled protein assemblies
T Schwarz-Romond, C Metcalfe, M Bienz
Journal of cell science 120 (14), 2402-2412, 2007
2832007
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function
EE Storm, S Durinck, F de Sousa E Melo, J Tremayne, N Kljavin, C Tan, ...
Nature 529 (7584), 97-100, 2016
2292016
Inhibition of GSK3 by Wnt signalling–two contrasting models
C Metcalfe, M Bienz
Journal of cell science 124 (21), 3537-3544, 2011
2202011
Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists
C Metcalfe, FJ de Sauvage
Cancer research 71 (15), 5057-5061, 2011
2072011
Therapeutic ligands antagonize estrogen receptor function by impairing its mobility
J Guan, W Zhou, M Hafner, RA Blake, C Chalouni, IP Chen, T De Bruyn, ...
Cell 178 (4), 949-963. e18, 2019
1512019
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
JD Joseph, B Darimont, W Zhou, A Arrazate, A Young, E Ingalla, K Walter, ...
Elife 5, e15828, 2016
1212016
Stability elements in the LRP6 cytoplasmic tail confer efficient signalling upon DIX-dependent polymerization
C Metcalfe, C Mendoza-Topaz, J Mieszczanek, M Bienz
Journal of cell science 123 (9), 1588-1599, 2010
1112010
GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer
J Liang, JR Zbieg, RA Blake, JH Chang, S Daly, AG DiPasquale, ...
Journal of Medicinal Chemistry 64 (16), 11841-11856, 2021
832021
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer
MR Junttila, V Devasthali, JH Cheng, J Castillo, C Metcalfe, AC Clermont, ...
Molecular cancer therapeutics 14 (1), 40-47, 2015
642015
PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition
C Metcalfe, B Alicke, A Crow, M Lamoureux, GJP Dijkgraaf, F Peale, ...
Cancer research 73 (23), 7034-7042, 2013
632013
Dvl2 Promotes Intestinal Length and Neoplasia in the ApcMin Mouse Model for Colorectal Cancer
C Metcalfe, AEK Ibrahim, M Graeb, M de la Roche, T Schwarz-Romond, ...
Cancer research 70 (16), 6629-6638, 2010
582010
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer
YC Chen, J Yu, C Metcalfe, T De Bruyn, T Gelzleichter, V Malhi, ...
Expert Opinion on Investigational Drugs 31 (6), 515-529, 2022
442022
Stromal Indian hedgehog signaling is required for intestinal adenoma formation in mice
NVJA Büller, SL Rosekrans, C Metcalfe, J Heijmans, WA Van Dop, ...
Gastroenterology 148 (1), 170-180. e6, 2015
412015
Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor …
MN Dickler, R Villanueva, JA Perez Fidalgo, IA Mayer, V Boni, EP Winer, ...
Cancer research 78 (4_Supplement), PD5-10-PD5-10, 2018
292018
Compressive stress-mediated p38 activation required for ERα+ phenotype in breast cancer
PM Munne, L Martikainen, I Räty, K Bertula, Nonappa, J Ruuska, ...
Nature communications 12 (1), 6967, 2021
262021
Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes
C Metcalfe, E Ingalla, RA Blake, J Chang, A Daemen, T De Bruyn, ...
Cancer Research 79 (4_Supplement), P5-04-07-P5-04-07, 2019
242019
A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2 …
K Jhaveri, EP Winer, E Lim, JA Perez Fidalgo, M Bellet, IA Mayer, V Boni, ...
Reason 1, 3, 2020
232020
Discovery of GNE-149 as a full antagonist and efficient degrader of estrogen receptor alpha for ER+ breast cancer
J Liang, R Blake, J Chang, LS Friedman, S Goodacre, S Hartman, ...
ACS Medicinal Chemistry Letters 11 (6), 1342-1347, 2020
212020
Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with …
HM Moore, V Boni, M Bellet, B Bermejo De Las Heras, M Gión Cortés, ...
Journal of Clinical Oncology 39 (15_suppl), 577-577, 2021
152021
The system can't perform the operation now. Try again later.
Articles 1–20